On Apr. 23, NJ LEG enacted bill on coverage for biomarker testing.
NJ LEG enacted AB 4163/SB 3098 requiring health insurers provide health insurance coverage for biomarker precision medical testing to treat, manage medical conditions.
Bill Provisions
State-regulated health insurance providers required to provide coverage for testing for diagnosis, treatment, management of disease when supported by medical evidence.
Subscriber, treating health care provider prescribing biomarker testing to have access to clear, conspicuous information on how to submit appeal to adverse determination.
Benefits shall be provided to the same extent as for any other medical condition under contract, including determinations of clinical review criteria used for utilization review.
Legislative History
On Apr. 8, 2024, bill delivered to Assembly; on Mar. 24, 2025, bill passed Assembly.
On Mar. 24, 2025, bill introduced in Senate; on Mar. 24. 2025, bill passed in Senate.
On Apr. 23, 2025, bill was approved by NJ governor, assigned P.L. 2025, Ch. 49.
Effectiveness
This act takes effect on 90th day next following enactment, on Jul. 22, 2025.
